Literature DB >> 25173817

Nucleolin enhances internal ribosomal entry site (IRES)-mediated translation of Sp1 in tumorigenesis.

Chia-Yang Hung1, Wen-Bin Yang2, Shao-An Wang2, Tsung-I Hsu3, Wen-Chang Chang4, Jan-Jong Hung5.   

Abstract

Our previous study indicated that specificity protein-1 (Sp1) is accumulated during hypoxia in an internal ribosomal entry site (IRES)-dependent manner. Herein, we found that the Sp1 was induced strongly at the protein level, but not in the mRNA level, in lung tumor tissue, indicating that translational regulation might contribute to the Sp1 accumulation during tumorigenesis. A further study showed that the translation of Sp1 was dramatically induced through an IRES-dependent pathway. RNA immunoprecipitation analysis of proteins bound to the 5'-untranslated region (5'-UTR) of Sp1 identified interacting protein - nucleolin. Knockdown of nucleolin significantly inhibited IRES-mediated translation of Sp1, suggesting that nucleolin positively facilitates Sp1 IRES activation. Further analysis of the interaction between nucleolin and the 5'-UTR of Sp1 mRNA revealed that the GAR domain was important for IRES-mediated translation of Sp1. Moreover, gefitinib, and LY294002 and MK2206 compounds inhibited IRES-mediated Sp1 translation, implying that activation of the epithelial growth factor receptor (EGFR) pathway via Akt activation triggers the IRES pathway. In conclusion, EGFR activation-mediated nucleolin phosphorylated at Thr641 and Thr707 was recruited to the 5'-UTR of Sp1 as an IRES trans-acting factor to modulate Sp1 translation during lung cancer formation.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EGFR; IRES; Nucleolin; Phosphorylation; Sp1

Year:  2014        PMID: 25173817     DOI: 10.1016/j.bbamcr.2014.08.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer.

Authors:  Yonggang Yang; Chunyan Yang; Jianping Zhang
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

Review 2.  More than just scanning: the importance of cap-independent mRNA translation initiation for cellular stress response and cancer.

Authors:  Rafaela Lacerda; Juliane Menezes; Luísa Romão
Journal:  Cell Mol Life Sci       Date:  2016-12-02       Impact factor: 9.261

3.  Nucleolin Promotes IRES-Driven Translation of Foot-and-Mouth Disease Virus by Supporting the Assembly of Translation Initiation Complexes.

Authors:  Shichong Han; Xiaojia Wang; Junyong Guan; Jinen Wu; Yun Zhang; Pinghua Li; Zaixin Liu; Sahibzada Waheed Abdullah; Zhihui Zhang; Ye Jin; Shiqi Sun; Huichen Guo
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

4.  Nm23-H1-stabilized hnRNPA2/B1 promotes internal ribosomal entry site (IRES)-mediated translation of Sp1 in the lung cancer progression.

Authors:  Chia-Yang Hung; Yi-Chang Wang; Jian-Ying Chuang; Ming-Jer Young; Hungjiun Liaw; Wen-Chang Chang; Jan-Jong Hung
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

Review 5.  Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis.

Authors:  Laura Sofia Carvalho; Nélio Gonçalves; Nuno André Fonseca; João Nuno Moreira
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

6.  Positive feedback regulation between IL10 and EGFR promotes lung cancer formation.

Authors:  Tsung-I Hsu; Yi-Chang Wang; Chia-Yang Hung; Chun-Hui Yu; Wu-Chou Su; Wen-Chang Chang; Jan-Jong Hung
Journal:  Oncotarget       Date:  2016-04-12

Review 7.  Cap-Independent Translation in Hematological Malignancies.

Authors:  Emilie Horvilleur; Lindsay A Wilson; Amandine Bastide; David Piñeiro; Tuija A A Pöyry; Anne E Willis
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244

8.  Inhibition of Specificity Protein 1 Is Involved in Phloretin-Induced Suppression of Prostate Cancer.

Authors:  Dan Kang; Wenren Zuo; Qingxin Wu; Qingyi Zhu; Ping Liu
Journal:  Biomed Res Int       Date:  2020-08-10       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.